Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as an anxiolytic and is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **LGS Seizures:** Initial dose: 5 mg twice daily.
* Titrate dose upward by 5-10 mg every week based on response and tolerability.
* Usual maintenance dose: 10-20 mg twice daily.
* Maximum dose: 20 mg twice daily (40 mg total daily dose).
## Pediatric Dosing
* **LGS Seizures (2 to <10 years of age or <30 kg):** Initial dose: 5 mg once daily.
* Titrate dose upward by 2.5-5 mg every week based on response and tolerability.
* Usual maintenance dose: 5-10 mg once daily.
* Maximum dose: 10 mg once daily.
* **LGS Seizures (10 years of age or older OR ≥30 kg):** Initial dose: 5 mg twice daily.
* Titrate dose upward by 5-10 mg every week based on response and tolerability.
* Usual maintenance dose: 10-20 mg twice daily.
* Maximum dose: 20 mg twice daily (40 mg total daily dose).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment is recommended, but close monitoring is advised.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, drooling, constipation, decreased appetite, fatigue, aggression, agitation, irritability, vomiting.
* **Serious:** Severe somnolence and sedation, suicidal behavior and ideation, withdrawal symptoms (including seizures), Stevens-Johnson syndrome, respiratory depression.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression, potentially leading to profound sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** May increase clobazam plasma concentrations.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam plasma concentrations.
* **CNS Stimulants:** May reduce the efficacy of CNS stimulants.
## Monitoring
* Monitor for excessive sedation and somnolence.
* Assess for changes in behavior, including suicidal ideation.
* Monitor for withdrawal symptoms upon discontinuation.
* Monitor seizure frequency and characteristics.
## Clinical Pearls
* Clobazam should be tapered gradually upon discontinuation to avoid withdrawal symptoms.
* Due to the risk of somnolence, patients should be cautioned about operating heavy machinery or driving until they know how clobazam affects them.
* Consider dose reduction in patients taking concomitant CYP3A4 inhibitors.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and management may vary based on individual patient factors and local protocols.
